Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEFAZOLIN SODIUM

All injection strengths: not a benefit

Other products in the same Health Canada class (J01D, J01DB) — coverage varies; not interchangeable

  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cephalexin (Ceporex): general benefit, Not a benefit
  • Cefixime (Suprax): general benefit
  • Cefprozil (Ran-Cefprozil): general benefit, Not a benefit
  • Ceftriaxone (Rocephin): general benefit, Not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit

1 more in the class list below

Cefazolin for Injection · DIN 02108127 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Cefazolin for Injection · DIN 02108127 Manufacturer: Teva Canada Limited; listing date 2010-06-14 Health Canada: Marketed since 2013-04-13 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19532 · Verify on the e-Formulary ↗ (DIN 02108127)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02108127). DIN 02108127: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id TEV Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02108127 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19532
Interchangeable products
Cefazolin for Injection · DIN 02297205 · $6.0000 Cefazolin for Injection · DIN 02437112 · $6.0000 Cefazolin for Injection USP · DIN 02308959 · $6.0000 Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: resolved shortage (ended 2023-08-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02108127
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection · DIN 02437112 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Cefazolin for Injection · DIN 02437112 Manufacturer: Sterimax Inc.; listing date 2022-01-31 Health Canada: Marketed since 2023-12-21 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Hikma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price $6.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92142 · Verify on the e-Formulary ↗ (DIN 02437112)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437112). DIN 02437112: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.0000; ministry $6.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437112 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92142
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded Cefazolin for Injection · DIN 02297205 · $6.0000 Cefazolin for Injection USP · DIN 02308959 · $6.0000 Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: resolved shortage (ended 2023-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437112
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection USP · DIN 02308959 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Cefazolin for Injection USP · DIN 02308959 Manufacturer: Sandoz Canada Inc.; listing date 2023-10-31 Health Canada: Marketed since 2008-04-18 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection USP: Formulary list price $6.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79456 · Verify on the e-Formulary ↗ (DIN 02308959)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02308959). DIN 02308959: Cefazolin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.0000; ministry $6.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02308959 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79456
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded Cefazolin for Injection · DIN 02297205 · $6.0000 Cefazolin for Injection · DIN 02437112 · $6.0000 Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: active shortage (reported 2026-08-10, estimated to end 2026-10-02, last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02308959
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection USP · DIN 02465469 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Cefazolin for Injection USP · DIN 02465469 Manufacturer: Sterimax Inc.; listing date 2023-09-28 Health Canada: Marketed since 2023-06-06 · brand CEFAZOLIN SODIUM FOR INJECTION BP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection USP: Formulary list price $6.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95364 · Verify on the e-Formulary ↗ (DIN 02465469)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02465469). DIN 02465469: Cefazolin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.0000; ministry $6.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465469 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95364
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded Cefazolin for Injection · DIN 02297205 · $6.0000 Cefazolin for Injection · DIN 02437112 · $6.0000 Cefazolin for Injection USP · DIN 02308959 · $6.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02465469
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection · DIN 02437120 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02437120 Manufacturer: Sterimax Inc.; listing date 2022-01-31 Health Canada: Marketed since 2024-02-14 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Hikma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price $56.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $56.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92143 · Verify on the e-Formulary ↗ (DIN 02437120)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437120). DIN 02437120: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $56.0000; ministry $56.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437120 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92143
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded Cefazolin for Injection · DIN 02297213 · $56.0000 Cefazolin for Injection USP · DIN 02308967 · $56.0000 Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: resolved shortage (ended 2023-06-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437120
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection USP · DIN 02308967 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection USP · DIN 02308967 Manufacturer: Sandoz Canada Inc.; listing date 2023-10-31 Health Canada: Marketed since 2008-04-18 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection USP: Formulary list price $56.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $56.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79457 · Verify on the e-Formulary ↗ (DIN 02308967)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02308967). DIN 02308967: Cefazolin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $56.0000; ministry $56.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02308967 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79457
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded Cefazolin for Injection · DIN 02297213 · $56.0000 Cefazolin for Injection · DIN 02437120 · $56.0000 Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: resolved shortage (ended 2026-04-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02308967
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection USP · DIN 02465477 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection USP · DIN 02465477 Manufacturer: Sterimax Inc.; listing date 2023-09-28 Health Canada: Marketed since 2023-06-06 · brand CEFAZOLIN SODIUM FOR INJECTION BP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Sterimax inc · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection USP: Formulary list price $56.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $56.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95365 · Verify on the e-Formulary ↗ (DIN 02465477)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02465477). DIN 02465477: Cefazolin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $56.0000; ministry $56.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465477 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95365
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded Cefazolin for Injection · DIN 02297213 · $56.0000 Cefazolin for Injection · DIN 02437120 · $56.0000 Cefazolin for Injection USP · DIN 02308967 · $56.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02465477
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection, USP · DIN 02237140 · 10g/Vial · powder for injection, vial (Preservative-Free)

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection, USP · DIN 02237140 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2025-08-29 Health Canada: Marketed since 2016-01-13 · brand CEFAZOLIN FOR INJECTION, USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection, USP: Formulary list price $56.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $56.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60455 · Verify on the e-Formulary ↗ (DIN 02237140)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02237140). DIN 02237140: Cefazolin for Injection, USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228194; group id 37; item number 0076; lccId None; manufacturer id FKC Source form: Inj Pd-Vial Pk (Preservative-Free); strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $56.0000; ministry $56.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237140 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60455
Interchangeable products
Ancef · DIN 01919628 · not recorded
Shortage status: resolved shortage (ended 2020-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237140
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection · DIN 02108119 · 500mg/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02108119 Manufacturer: Teva Canada Limited; listing date 2022-01-31 Health Canada: Marketed since 2013-04-13 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 500 MG/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19521 · Verify on the e-Formulary ↗ (DIN 02108119)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02108119). DIN 02108119: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228112; group id 37; item number 0073; lccId None; manufacturer id TEV Source form: Inj Pd-Vial Pk; strength: 500mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02108119 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19521
Interchangeable products
Cefazolin for Injection · DIN 02437104 · $4.0000 Cefazolin for Injection USP · DIN 02308932 · $4.0000
Shortage status: discontinued (2019-07-31, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02108119
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection · DIN 02437104 · 500mg/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02437104 Manufacturer: Sterimax Inc.; listing date 2022-01-31 Health Canada: Marketed since 2025-02-06 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 500 MG/VIAL · company Hikma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price $4.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92141 · Verify on the e-Formulary ↗ (DIN 02437104)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437104). DIN 02437104: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228112; group id 37; item number 0073; lccId None; manufacturer id STE Source form: Inj Pd-Vial Pk; strength: 500mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $4.0000; ministry $4.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437104 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92141
Interchangeable products
Cefazolin for Injection · DIN 02108119 · not recorded Cefazolin for Injection USP · DIN 02308932 · $4.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437104
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection USP · DIN 02308932 · 500mg/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection USP · DIN 02308932 Manufacturer: Sandoz Canada Inc.; listing date 2023-10-31 Health Canada: Marketed since 2008-04-18 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 500 MG/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection USP: Formulary list price $4.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79454 · Verify on the e-Formulary ↗ (DIN 02308932)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02308932). DIN 02308932: Cefazolin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228112; group id 37; item number 0073; lccId None; manufacturer id SDZ Source form: Inj Pd-Vial Pk; strength: 500mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $4.0000; ministry $4.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02308932 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79454
Interchangeable products
Cefazolin for Injection · DIN 02108119 · not recorded Cefazolin for Injection · DIN 02437104 · $4.0000
Shortage status: resolved shortage (ended 2024-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02308932
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefazolin for Injection · DIN 02297205 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued 2019-06-28 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Cefazolin for Injection · DIN 02297205 Manufacturer: Orchid Healthcare; listing date 2010-06-14 Health Canada: Cancelled post market since 2019-06-28 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price $6.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78258 · Verify on the e-Formulary ↗ (DIN 02297205)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02297205). DIN 02297205: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id ORC Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $6.0000; ministry $6.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78258
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded Cefazolin for Injection · DIN 02437112 · $6.0000 Cefazolin for Injection USP · DIN 02308959 · $6.0000 Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297205
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.

Cefazolin for Injection · DIN 02108135 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.Discontinued 2022-09-27 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02108135 Manufacturer: Teva Canada Limited; listing date 2010-06-14 Health Canada: Cancelled post market since 2022-09-27 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19534 · Verify on the e-Formulary ↗ (DIN 02108135)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02108135). DIN 02108135: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id TEV Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02108135 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19534
Interchangeable products
Cefazolin for Injection · DIN 02297213 · $56.0000 Cefazolin for Injection · DIN 02437120 · $56.0000 Cefazolin for Injection USP · DIN 02308967 · $56.0000 Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: discontinued (2023-03-31, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02108135
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.

Cefazolin for Injection · DIN 02297213 · 10g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued 2019-06-28 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02297213 Manufacturer: Orchid Healthcare; listing date 2010-06-14 Health Canada: Cancelled post market since 2019-06-28 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Cefazolin for Injection: Formulary list price $56.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $56.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78259 · Verify on the e-Formulary ↗ (DIN 02297213)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02297213). DIN 02297213: Cefazolin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id ORC Source form: Inj Pd-Vial Pk; strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $56.0000; ministry $56.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297213 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78259
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded Cefazolin for Injection · DIN 02437120 · $56.0000 Cefazolin for Injection USP · DIN 02308967 · $56.0000 Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297213
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.

Ancef · DIN 01919628 · 10g/Vial · powder for injection, vial (Preservative-Free)

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.Discontinued 2000-07-25 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection For treatment of infections susceptible to cefazolin. Standard Approval Duration: As requested up to 5 years EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Ancef · DIN 01919628 Manufacturer: Smith Kline Beecham Pharma Inc; listing date 2025-08-29 Health Canada: Cancelled post market since 2000-07-25 · brand ANCEF INJ PWS 10GM/VIAL USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Smithkline beecham pharma division of smithkline beecham inc · schedule Prescription
Check this DIN again · Health Canada product record

Ancef: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12914 · Verify on the e-Formulary ↗ (DIN 01919628)

Source record
DIN 01919628: Ancef Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 081228194; group id 37; item number 0076; lccId None; manufacturer id SMJ Source form: Inj Pd-Vial Pk (Preservative-Free); strength: 10g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01919628 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12914
Interchangeable products
Cefazolin for Injection, USP · DIN 02237140 · $56.0000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01919628
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications CEFAZOLIN FOR INJECTION (cefazolin sodium) is indicated in the treatment of the following infections when caused by susceptible strains of the listed organisms: Respiratory Tract Infections caused by Streptococcus pneumoniae, Klebsiella pneumoniae, Hemophilus influenzae, Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta- haemolytic streptococci. Urinary Tract Infections caused by Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae and some strains of enterobacter, and enterococci. See note below. Skin and Soft Tissue Infections caused by Staphylococcus aureus (penicillin-sensitive and penicillin- resistant), group A beta-haemolytic streptococci and other strains of streptococci. Bone and Joint Infections caused by Staphylococcus aureus. Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillin-sensitive and penicillin resistant), Proteus Mirabilis, Escherichia coli and Klebsiella pneumoniae. See note below. Endocarditis caused by Staphylococcus aureus (penicillin-sensitive and penicillin-resistant) and group A beta haemolytic streptococci. Determine susceptibility of the causative organism to c… https://pdf.hres.ca/dpd_pm/00082995.PDF PM date: 2025-12-29 Source product: CEFAZOLIN FOR INJECTION; DIN 02108119; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Cefazolin for Injection USP · DIN 02308959 Shortage status: active shortage (reported 2026-08-10, estimated to end 2026-10-02, last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02308959

Check this DIN again

Cefazolin for Injection · DIN 02108119 Shortage status: discontinued (2019-07-31, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02108119

Check this DIN again

Cefazolin for Injection · DIN 02108135 Shortage status: discontinued (2023-03-31, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02108135

Check this DIN again

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Cefazolin (Many Generic Brands)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For treatment of infections susceptible to cefazolin.

Ministry criteria corpus 2025-01-01; page 462

Cefazolin Brand(s): Many Generic Brands DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Cefazolin for Injection, Cefazolin for Injection USP, Cefazolin for Injection, USP, Ancef: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026